Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06560424 · ClinicalTrials.gov registry record
Cardiovascular and Metabolic Sciences Biorepository
A clinical trial of Cardiovascular Diseases and Metabolic Disease, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 1
- Study location
NCT06560424: Recruiting study of Cardiovascular Diseases and Metabolic Disease, sponsored by The Cleveland Clinic.
NCT06560424 is a study of Cardiovascular Diseases and Metabolic Disease that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 10,000 participants, below the 26,941-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06560424, a study of Cardiovascular Diseases and Metabolic Disease, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the Cardiovascular and Metabolic Sciences Biorepository is to collect and store information and biospecimens (blood, urine, stool, and heart tissue) from patients with and without cardiovascular and metabolic diseases to create a readily available biorepository of samples and related medical health information to expedite future research into the causes and consequences of cardiovascular and metabolic diseases.
Primary Outcome
Establish a biorepository of samples (blood, urine, stool, and heart tissue) and related medical health information to support future investigation into cardiovascular and metabolic diseases.
Conditions Studied
Study Locations (1)
Ohio
- Cleveland Clinic Main Campus - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2024-09-18 |
| Est. Completion | 2050-12-31 |
What NCT06560424 shows while recruiting
NCT06560424 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, below the 26,941-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 0 interventions.
NCT06560424 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06560424 about?
NCT06560424 is a clinical study titled "Cardiovascular and Metabolic Sciences Biorepository". The purpose of the Cardiovascular and Metabolic Sciences Biorepository is to collect and store information and biospecimens (blood, urine, stool, and heart tissue) from patients with and without cardiovascular and metabolic diseases to create a readily available biorepository of samples and related ...
What is the current status of trial NCT06560424?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2024-09-18. Estimated completion is 2050-12-31.
What conditions does trial NCT06560424 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Metabolic Disease.
Who is sponsoring clinical trial NCT06560424?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06560424 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06560424's enrollment target sits among peer trials
10,000 14th of 300 higher than 285 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)
RECRUITING
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI